Bassil Dahiyat Sells 14,870 Shares of Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil Dahiyat sold 14,870 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $167,287.50. Following the sale, the chief executive officer directly owned 552,922 shares in the company, valued at approximately $6,220,372.50. This represents a 2.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Xencor Trading Up 0.9%

Shares of Xencor stock opened at $11.98 on Wednesday. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $18.69. The company has a current ratio of 6.25, a quick ratio of 6.25 and a debt-to-equity ratio of 0.12. The stock has a market cap of $878.61 million, a PE ratio of -9.66 and a beta of 0.95. The company has a 50-day moving average of $12.67 and a two-hundred day moving average of $13.06.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.55. The business had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The company’s quarterly revenue was down 46.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.62) EPS. On average, research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on XNCR. Truist Financial started coverage on Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 target price on the stock. Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Finally, Barclays raised their target price on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Trending Headlines about Xencor

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Xencor reported an earnings beat on Feb. 25 (EPS -$0.09 vs. consensus -$0.64), which can support sentiment despite revenue weakness; investors often reward upside to EPS expectations. Earnings Summary
• Positive Sentiment: Analyst coverage includes new/raised targets (Truist coverage with a Buy, Barclays raising its target to $27), which provides external validation and upside to the consensus price target (~$25). Analyst Notes
• Neutral Sentiment: Institutional holders show modest position changes (small increases by several funds); these are routine rebalances and not a clear directional signal. Institutional Activity
• Negative Sentiment: Xencor and Genentech agreed to end their protein-therapeutics collaboration — this removes a strategic partner that could have provided development resources, milestones or royalties; termination may return rights to Xencor but creates near-term uncertainty for the affected programs and potential revenue. Xencor, Genentech to End Protein Therapeutics Collaboration
• Negative Sentiment: Clustered insider selling by senior executives was disclosed this week: CEO Bassil Dahiyat sold ~21,476 shares across Mar 5–6, SVP Celia Eckert sold ~5,011 shares, and VP John Desjarlais sold ~6,620 shares (transactions at ~$11–$11.90 per share). While each sale reduces insider holdings only a few percent, the timing and concentration can be read negatively absent a disclosed 10b5‑1 plan. Relevant filings: CEO Form 4(s) SVP Form 4(s) VP Form 4(s)

Hedge Funds Weigh In On Xencor

A number of institutional investors have recently made changes to their positions in the stock. Amalgamated Bank lifted its position in shares of Xencor by 4.8% in the third quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company’s stock valued at $245,000 after acquiring an additional 947 shares in the last quarter. ProShare Advisors LLC increased its position in Xencor by 6.5% during the 4th quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 1,026 shares in the last quarter. Cerity Partners LLC raised its stake in Xencor by 3.8% in the 4th quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock valued at $479,000 after purchasing an additional 1,143 shares during the last quarter. HighVista Strategies LLC raised its stake in Xencor by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 1,362 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 1,449 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.